D-Ribo-2-Hexulose Composition for Exercise-Independent Sarcopenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and preventive measures for sarcopenia, a condition characterized by rapid muscle mass loss with aging, are inadequate in effectively increasing muscle mass and strength without exercise.
Innovation Solution
A pharmaceutical and food composition containing D-ribo-2-hexulose as an active ingredient, which increases muscle mass and strength by enhancing insulin-like growth factor 1 (IGF-1) expression, inhibiting myostatin, and promoting muscle protein synthesis through pathways like PI3K/Akt and mTOR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If conventional treatments are used for sarcopenia, then muscle mass loss is addressed, but muscle mass and strength cannot be effectively increased without exercise
Solution Approach 1:
The patent replaces the mechanical system of exercise training with a pharmaceutical composition containing D-ribo-2-hexulose. The composition acts on molecular pathways (IGF-1, myostatin, PI3K/Akt, mTOR) to achieve muscle mass and strength increases without requiring mechanical exercise input, thereby substituting physical effort with biochemical intervention.
Solution Approach 2:
The patent changes the biochemical parameters of muscle protein synthesis and degradation by introducing D-ribo-2-hexulose, which modulates key signaling pathways. This chemical parameter intervention achieves the same functional outcome (increased muscle mass and strength) that would otherwise require changes in physical activity parameters through exercise.
2Reliability
If D-ribo-2-hexulose is used to increase muscle mass, then sarcopenia is treated, but the substance must be safely synthesized and produced at scale
Solution Approach 1:
The patent utilizes D-ribo-2-hexulose, a monosaccharide that is naturally occurring and GRAS (generally recognized as safe) by the USDA. Rather than requiring complex synthesis, the approach uses this safe, naturally-derived substance that can be produced through relatively simple enzymatic methods from common sugars like fructose or sucrose, prioritizing safety and ease of production over complexity.
Solution Approach 2:
The patent employs enzymatic intermediaries (D-tagatose epimerase or D-ribo-2-hexulose epimerase) to convert fructose into D-ribo-2-hexulose. These enzymes act as mediators that enable the transformation using mild, controlled conditions, avoiding the need for harsh chemical synthesis while maintaining high yield and purity of the active ingredient.
3Strength
If D-ribo-2-hexulose is administered to increase muscle mass, then muscle protein synthesis is promoted, but blood sugar levels may be affected
Solution Approach 1:
The patent changes the metabolic parameter of blood sugar by using D-ribo-2-hexulose, which has a low glycemic index and does not cause significant blood sugar spikes. The substance is metabolized differently than conventional sugars, providing energy without the same metabolic burden, thus allowing muscle protein synthesis promotion without excessive blood sugar elevation.
Solution Approach 2:
The patent converts the potential harm of sugar administration (blood sugar elevation) into a benefit by selecting D-ribo-2-hexulose, which has minimal impact on blood sugar. The substance provides the necessary energy and metabolic signaling for muscle growth while avoiding the harmful effect of hyperglycemia, turning a potential negative into a positive outcome.
Data Source
AI summary
The present invention relates to a composition for preventing, alleviating or treating sarcopenia, containing D-ribo-2-hexulose as an active ingredient. D-ribo-2-hexulose of the present invention is a sweetener capable of replacing sugar, is harmless to the human body and does not cause side effects in normal cells so as to be safe for the human body, inhibits the degradation of myoproteins, and can exhibit muscle strengthening effects by increasing muscle mass, and thus the present invention is expected to be effectively usable in the prevention, alleviation or treatment of sarcopenia.